BioSpace News Archive

CirrusMD, a leading provider of on-demand virtual care, today announced the CirrusMD Provider Network (CMDPN) has achieved the ISO/IEC 27001:2013 certification for its information security management system.

The Prostate Cancer Foundation (PCF) today announced the 2022 Class of PCF Team Challenge Award recipients and a total of more than $12 million in funding for innovative prostate cancer research.

AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic pain syndromes, such as fibromyalgia.

Biological Dynamics, a company commercializing its exosome-isolation ExoVerita™ platform, announced a collaboration with the Perlmutter Cancer Center at NYU Langone Health to validate its application for the early detection of pancreatic ductal adenocarcinoma.

Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”) today announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional accredited investor.

The completely unique mechanism of action of the world’s first COVID-19 vaccine to stimulate “high affinity” antibodies which neutralise most COVID variants has been published by EnGeneIC in the prestigious journal, Frontiers in Immunology (27th January, 2023).

Alignment Healthcare, Inc. (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, will release its fourth quarter and full-year 2022 financial results on Tuesday, Feb. 28, after market close.

SeaStar Medical announces that Eric Schlorff, CEO, will present a company overview at the virtual Sequire Biotechnology Conference on Thursday, February 2 at 3:30 p.m. Eastern time.

Shockwave Medical, Inc. (NASDAQ: SWAV) today announced that coronary IVL was included in a treatment guidance document published by the Society of Cardiovascular Angiography and Intervention (SCAI) as a potential therapeutic option in all U.S. catheterization labs. - including facilities without on-site surgical backup.

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced the publication of a comparative study of BrainsWay’s Deep Transcranial Stimulation H1 Coil, which targets the lateral prefrontal cortex, and the Company’s H7 Coil, which targets the medial prefrontal cortex.